T richosporon species can cause biofilm-associated infections related to indwelling medical devices, especially intravenous catheters, and unacceptable mortality rates have been reported despite the administration of antifungal treatments (1). Trichosporon asahii can form biofilms with structured microbial communities in vitro, embedded within an extracellular matrix, with significantly increased resistance to antifungal compounds (2, 3), which might ultimately lead to clinical treatment failure. Antifungal combination may be an alternative therapy strategy for biofilm-related fungal infections (4). The synergistic effects of antifungal combinations against other fungal biofilms have been detected in vitro, such as amphotericin B-posaconazole for Candida albicans (5) and amphotericin B-caspofungin or voriconazole-caspofungin for Aspergillus spp. (6). The synergistic effects of antifungal combinations of voriconazole, amphotericin B, and caspofungin against planktonic T. asahii have been found in vitro (7). We evaluated the in vitro activity of the combinations of voriconazole-amphotericin B, voriconazole-caspofungin, and amphotericin B-caspofungin against 16 clinical isolates of T. asahii in biofilm and planktonic forms by a broth microdilution checkerboard method (5). Trichosporon biofilms were prepared according to the 96-well plate-based method (8). The effect of antifungal agents was determined by the 2,3-bis(2-methoxy-4-nitro-5-[(sulfenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT)-based colorimetric assay for both biofilms and planktonic cells (5, 8) . The MIC and sessile MIC (SMIC) were determined as the lowest antifungal concentration (alone or in combination) that caused a 50% reduction in optical density for both biofilms and planktonic cells compared with the growth control (5, 6). The interaction was defined on the basis of the fractional inhibitory concentration indexes (FICIs) as follows: Յ0.5, synergy; Ͼ0.5 to 4, indifference; and Ͼ4.0, antagonism.
, and even the decreased SMICs of the voriconazole-amphotericin B combination are still higher than the highest plasma drug concentrations safely used in clinical practice. For patients needing catheter salvage due to limited venous access or catheter reinsertion or for those with thrombocytopenia or some other coagulopathy, the use of a single antifungal agent as a lock solution (0.33 to 5 mg/ml for amphotericin B or 3.33 mg/ml for caspofungin) in antifungal lock therapy has been utilized in the management of Candida CR-BSIs (10). However, a single antifungal agent (caspofungin or amphotericin B) may be not suitable for use as a lock solution for T. asahii CR-BSIs because the paradoxical growth of T. asahii biofilms was observed at high doses (512 to 1,024 g/ml) of caspofungin in our study, and the SMICs indicated the lower activity of amphotericin B against T. asahii biofilms (32 to 1,024 g/ml) than Candida albicans biofilms (2 to 4 g/ml) (5). The synergistic effect of the voriconazole-amphotericin B combination against T. asahii biofilms was achieved along with a significant decrease in the SMICs of voriconazole (up to 256-fold) and amphotericin B (up to 128-fold) when used in combination. Thus, the synergistic voriconazole-amphotericin B combination may be an option as a lock solution for T. asahii CR-BSIs, especially for patients who are catheter dependent or have risks associated with catheter removal.
